Dario A. Paggiarino - 04 Dec 2023 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Signature
/s/ Ron Honig, Attorney-in-Fact
Issuer symbol
EYPT
Transactions as of
04 Dec 2023
Net transactions value
-$363,519
Form type
4
Filing time
06 Dec 2023, 17:19:35 UTC
Previous filing
22 Jun 2023
Next filing
15 Dec 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EYPT Common Stock Options Exercise $310,231 +30,625 +119% $10.13 56,332 04 Dec 2023 Direct
transaction EYPT Common Stock Sale $673,750 -30,625 -54% $22.00 25,707 04 Dec 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EYPT Stock Option (Right to Buy) Options Exercise $0 -30,625 -44% $0.000000 39,375 04 Dec 2023 Common Stock 30,625 $10.13 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The option to purchase will vest and become exercisable as follows: 25% at February 9th, 2023 and the remainder ratably, on a monthly basis, over the remaining three years.